NCCN Referencing Guidance

1. What should my organization consider when developing language regarding NCCN Content?
   - **Generic Drug Names** - NCCN Guidelines always recommend the generic drug name, and do not recommend a brand. For licensed use for commercial purposes, we do allow the use of “generic (brand name)” when citing the NCCN recommendations.
     - Example: [Generic name (brand name)] is a recommended option within NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in [setting and cancer type].
   - **NCCN Recommendation is a treatment OPTION** - Statements should make it clear that a particular product/recommendation is an “option.”
     - Example: [Generic name (brand name)] is recommended by the National Comprehensive Cancer Network® (NCCN®) as a treatment option for [setting and cancer type].
   - **The term “certain patients” may be used** if the full NCCN recommendation cannot be listed on a piece due to regulatory requirements or space limitations.
     - Example: [Generic name (brand name)] is recommended by the National Comprehensive Cancer Network® (NCCN®) as a treatment option for certain patients with [cancer type].
   - **If including both the NCCN Category of Evidence and the NCCN Category of Preference**, the Category of Evidence should be first, followed by the Category of Preference.
     - Example: [Generic name (brand name)] is recommended by the National Comprehensive Cancer Network® (NCCN®) as a Category 2A, Preferred treatment option for [setting and cancer type].
   - **Avoid the phrase, “standard of care”** when referring to recommendations in the NCCN Guidelines due to potential legal implications.
   - **Caution should be used when making “only” statements regarding NCCN Guidelines** – the requestor should ensure that these statements are factually accurate and that they may need to changed based on future guideline updates.
   - **Stay true to how the NCCN recommendation is written and avoid subjective commentary.**
     - For example, avoid “highest recommendation,” use “preferred” only when explicitly noted, and avoid oversimplification of recommendations.

2. What trademarking conventions should I use when mentioning NCCN or the NCCN Guidelines?
   - **When “NCCN” is mentioned:**
     - First Mention: National Comprehensive Cancer Network® (NCCN®)
     - All Other Mentions: NCCN
   - **When “NCCN Guidelines” are mentioned:**
     - First Mention: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
     - Second Mention: NCCN Guidelines®
     - All Other Mentions: NCCN Guidelines
   - **Please note that trademarks cannot be combined**
   - **When other NCCN content (e.g., Guidelines for Patients, Guidelines with Evidence Blocks, etc.) are mentioned**: please reach out to the Permissions team member who is managing your request with additional trademarking rules specific to the NCCN content you are referencing.
3. What is the proper way to reference/adapt/reproduce the NCCN Guidelines in my piece?
   - **Proper citing when Referencing:**
     - Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © National Comprehensive Cancer Network, Inc. 202X. All rights reserved. Accessed [Month and Day, Year]. To view the most recent and complete version of the guideline, go online to NCCN.org.
   - **Proper citing when adapting an NCCN figure/algorithm:**
     - Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © 202X National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.
   - **Proper citing when reproducing an NCCN figure/algorithm:**
     - Reproduced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.X.202X. © 202X National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

4. Anything else I should be sure to include?
   - The following statement must be included on all materials that reference NCCN or the NCCN Guidelines: NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.